Norway· NO-ID_A8F1811A-7319-4F09-8E22-7E1B89964853

Imnovid

A pomalidomide product containing pomalidomide, registered in Norway by Bristol-Myers Squibb Pharma EEIG (1). The same ATC class is registered in 17 of our 19 countries.

ATC L04AX06

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedImnovidATCL04AX06REGISTER NO.NO-ID_A8F1811A-7319-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Pomalidomide is registered in 17 of 19 countries.

Countries holding a registration under ATC L04AX06 (pomalidomide), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 9 of them publish a price we can compare per daily dose

Pomalidomide · ATC L04AX06

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pomalidomide costs, country by country.

Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Pomalidomide · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$255.48
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FEST (Norway)
Active substance
Pomalidomide
Manufacturer
Bristol-Myers Squibb Pharma EEIG (1)
Country
Norway (NO)
ATC code
L04AX06
ATC class
Pomalidomide
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_A8F1811A-7319-4F09-8E22-7E1B89964853
  • no_varenummer
    554720
    21
    NOK 40468
  • gtin
    7640133683638

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

277 interactions on record for pomalidomide.

Graded by severity as the source publishes them — 64 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pomalidomide · interactions on record

277 records

  • 64 severe
  • 213 moderate

Most severe, free to view

  • ErythropoietinB03XA01severe
  • Darbepoetin alfaB03XA02severe
  • PeginesatideB03XA04severe
  • C1-inhibitor, plasma derivedB06AC01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pomalidomide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pomalidomide products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Pomalidomid +pharma, Pomalidomid Devatis
  • Belgium · Pomalidomide Eg, Pomalidomide Eugia
  • Bulgaria · Помалидомид Devatis, Помалидомид Булгермед
  • Cyprus · Pomalidomide, Pomalidomide Adalvo
  • Czechia · Pomalidomid Sanexcel, Pomalidomide Abdi
  • Germany · Pomadel, Pomalidomid 123 Acurae Pharma
  • Denmark · Pomalidomid Devatis, Pomalidomid Grindeks
  • Estonia · Pomalidomide Grindeks, Pomalidomide Olpha
  • Spain · Pomalidomida Abdi, Pomalidomida Erawya
  • Finland · Pomalidomid Avansor, Pomalidomid Devatis
  • France · Pomalidomide Eg, Pomalidomide Eugia
  • United Kingdom (Northern Ireland) · Pomalidomide, Pomalidomide Amarox
  • Greece · Polidma, Pomalidomide Anabiosis
  • Hungary · Pomalidomid Onkogen, Pomalidomide Grindeks
  • Ireland · Pomalidomide Clonmel, Pomalidomide Grindeks
  • Iceland · Imnovid, Pomalidomide Accord
  • Italy · Pomalidomide Abdi, Pomalidomide Aurobindo
  • Liechtenstein · Imnovid, Pomalidomide Accord
  • Lithuania · Pomalidomide Grindeks, Pomalidomide Olpha
  • Luxembourg · Pomalidomide Eg, Pomalidomide Eugia
  • Latvia · Pomalidomide Grindeks, Pomalidomide Olpha
  • Malta · Pomalidomide, Pomalidomide Clonmel
  • Netherlands · Polidma, Pomalidomide Adalvo
  • Poland · Pomalidomid Reig Jofre, Pomalidomide Eugia
  • Portugal · Pomalidomida Aurobindo, Pomalidomida Bluepharma
  • Romania · Pomalidomidă Dr. Reddy’s, Pomalidomidă Grindeks
  • Sweden · Davunfite, Pomalidomid Avansor
  • Slovenia · Pomadel, Pomalidomid Grindeks
  • Slovakia · Pomalidomid Grindeks, Pomalidomid Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c86a1c9e-c908-41f0-8432-2c8b6a31be0a
GET /v1/drugs/c86a1c9e-c908-41f0-8432-2c8b6a31be0a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsel, hard",
  "source": "fest",
  "status": "A",
  "atc_name": "Pomalidomid",
  "merkevare_id": "ID_A8F1811A-7319-4F09-8E22-7E1B89964853",
  "name_form_strength": "Imnovid kaps 3 mg",
  "prescription_group": "C"
}

See everything about pomalidomide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.